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Phenylarsine Oxide Blocks Interleukin-1b–Induced Activation
of the Nuclear Transcription Factor NF-kB, Inhibits Proliferation,
and Induces Apoptosis of Acute Myelogenous Leukemia Cells
By Zeev Estrov, Sunil K. Manna, David Harris, Quin Van, Elihu H. Estey, Hagop M. Kantarjian,
Moshe Talpaz, and Bharat B. Aggarwal
Arsenic compounds have recently been shown to induce
high rates of complete remission in patients with acute
promyelocytic leukemia (APL). One of these compounds,
As2O3, induces apoptosis in APL cells via a mechanism
independent of the retinoic acid pathway. To test the hypoth-
esis that arsenic compounds may be effective against other
forms of acute myelogenous leukemia (AML), we studied the
membrane-permeable arsenic compound phenylarsine ox-
ide (PAO). Because interleukin-1b (IL-1b) plays a key role in
AML cell proliferation, we first tested the effect of PAO on
OCIM2 and OCI/AML3 AML cell lines, both of which produce
IL-1b and proliferate in response to it. We found that PAO
inhibited the proliferation of both OCIM2 and OCI/AML3 cells
in a dose-dependent fashion (0.01 to 0.1 mmol/L) and that
IL-1b partially reversed this inhibitory effect. We then mea-
sured IL-1b levels in these cells by using an enzyme-linked
immunosorbent assay and Western immunoblotting and
found that PAO almost completely abolished the production
of IL-1b in these AML cells, whereas it did not affect the
production of IL-1 receptor antagonist. Because PAO inhibits
activation of the transcription factor NF-kB and because
NF-kB modulates an array of signals controlling cellular
survival, proliferation, and cytokine production, we also
studied the effect of PAO on NF-kB activation in AML cells
and found that PAO suppressed the IL-1b–induced activation
of NF-kB. Because inhibition of NF-kB may result in cellular
apoptosis, we also tested whether PAO may induce apop-
totic cell death in AML cells. We found that PAO induced
apoptosis in OCIM2 cells through activation of the cystein
protease caspase 3 and subsequent cleavage of its substrate,
the DNA repair enzyme poly (ADP-ribose) polymerase. The
PAO-induced apoptosis was caspase dependent, because it
was completely blocked by the caspase inhibitor Z-DEVD-
FMK. Finally, we tested the effect of PAO on fresh AML
marrow cells from 7 patients with newly diagnosed AML and
found that PAO suppressed AML colony-forming cell prolif-
eration in a dose-dependent fashion. Taken together, our
data showing that PAO is an effective in vitro inhibitor of
AML cells suggest that this compound may have a role in
future therapies for AML.
r 1999 by The American Society of Hematology.
A
CUTE MYELOGENOUS leukemia (AML) is a clonal
hematologic malignancy characterized by abnormal pro-
liferation of myeloid leukemia cells. Despite extensive clinical
research with numerous combinations of cytotoxic agents, the
overall prognosis of patients withAMLremains poor (reviewed
in Estey1). Thus, the search for more effective agents continues.
Arsenic compounds, such as arsenic trioxide (As2O3) and
arsenic disulﬁde,2 which are occasionally used in traditional
Chinese medicine, were found to induce complete remission
lasting for varying lengths of time in more than 70% of patients
with acute promyelocytic leukemia (APL).3 In a recent study by
Chen et al,4As2O3 induced apoptosis inAPL cells. Because this
apoptosis induction occurred independently of the retinoid
pathway,4 we therefore hypothesized that arsenic compounds
may effectively inhibit other forms ofAML.
To test our hypothesis, we used phenylarsine oxide (PAO).
This arsenic compound, which is structurally different from the
arsenicals mentioned above, is a membrane-permeable mol-
ecule that inhibits phosphotyrosine phosphatase (PTPase).5
Inhibition of PTPase by agents such as PAO, in turn, inactivates
the transcription factor NF-kB in various cell types, including
hematopoietic cells.6 NF-kB modulates the effects of various
transcription factors responsible for the proliferation of normal
myeloid and leukemia cells,7 and its activation induces the
expression of various cytokines, including interleukin-1b (IL-
1b; reviewed in Seibenlist et al8). IL-1b itself is a proinﬂamma-
tory cytokine that plays a major role in stimulating the
proliferation of AML cells.9-12 Thus, because PAO seemed to
possess properties sufficient to inhibitAMLcells, we studied its
effects onAML cell lines and on fresh bone marrow (BM) cells
from 7 patients with newly diagnosedAML.
Consequently, we found that PAO inhibited the proliferation
of both AML cell lines and fresh AML marrow blast colony-
forming cells and that PAO also inhibited the IL-1b–induced
activation of NF-kB and activated caspase 3, thus inducing
apoptotic cell death inAMLcells.
MATERIALS AND METHODS
Cell lines. The AML cell lines OCI/AML313 and OCIM214 were
kindly provided by M.D. Minden (Ontario Cancer Institute, Toronto,
Ontario, Canada). OCI/AML3 was established from an AML patient
and OCIM2 from a patient with erythroleukemia. Both cell lines
proliferate in the presence of culture medium and fetal calf serum (FCS)
without exogenous growth factors. The leukemia cell lines HL60 and
K562 were obtained from the American Type Culture Collection
(ATCC; Rockville, MD). All cells were maintained in RPMI-1640
culture medium (GIBCO, Grand Island, NY) supplemented with 10%
FCS (Flow Laboratories, McLean, VA).
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high marrow blast counts (see Table 1 for clinical data).All studies were
performed with the patients’ informed consent and were approved by
the Human Experimentation Committee of our institution.
Cell line clonogenic assay. Clonogenic assays were performed as
previously described.15 Brieﬂy, OCI/AML3, OCIM2, HL60, and K562
cells (2 to 4 3 104 cells/mL) were cultured in 0.8% methylcellulose
(Fluka Chemical Corp, Ronkonkoma, NY), 10% FCS, and RPMI-1640
medium in the presence of PAO (Aldrich, Milwaukee, WI), which was
dissolved in dimethyl sulfoxide (DMSO) at a concentration of less than
0.1%, with or without 10 ng/mL recombinant human (rh) IL-1b
(molecular weight 17,500; Boehringer Mannheim Biochemicals, India-
napolis, IN). The culture mixture was placed in 35-mm Petri dishes
(Nunc Inc, Naperville, IL) in duplicate or triplicate and maintained at
37°C with 5% CO2 in air in a humidiﬁed atmosphere. Colonies were
counted after 7 days by using an inverted microscope. A colony was
deﬁned as a cluster of more than 40 cells.
Enzyme-linked immunosorbent assay (ELISA). ELISAs were per-
formed with IL-1b and IL-1 receptor antagonist (IL-1RA) ELISA kits
(Cistron Biotechnology [Pine Brook, NJ] and Amersham Life Science
[Arlington Heights, IL], respectively) as previously described.16 Cell
lysates and standard dilutions of either IL-1b or IL-1RA were added to
test wells in duplicate and incubated for 2 hours at 37°C. The test wells
were then washed 3 times with phosphate-buffered saline (PBS),
incubated with rabbit IL-1b antiserum for 2 hours, washed as previ-
ously described, and incubated for 30 minutes with goat antirabbit IgG
conjugated to horseradish peroxidase. The test wells were vigorously
washed, and a substrate (o-phenylenediamine dissolved in 3% hydrogen
peroxide solution) and 4 N sulfuric acid were added. The color intensity
was read within 15 minutes at a wavelength of 490 nm with a microplate
autoreader (Model EL-309; Biotek, Winooski, VT). The average net
optical densities (OD) of the standard IL-1b and IL-1RAconcentrations
were then plotted, and the amount of the corresponding cytokine in each
sample was determined by interpolation from the standard curve.
Western immunoblotting for detection of IL-1b. Cell lysates were
assayed for protein concentration with the BCA Protein Assay Reagent
kit (Pierce Chemical Co, Rockford, IL). Each set of paired samples was
then adjusted to have the same protein concentration. Sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) analysis was
performed by using a modiﬁcation of the method of Laemmli.17 In brief,
antigens were dissolved in Laemmli sample buffer at room temperature.
Electrophoresis was conducted at a constant wattage (10 W) in running
buffer cooled to 4°C. Stacking gels contained 4% (wt/vol) acrylamide,
and separating gels contained 12% (wt/vol) acrylamide.Approximately
200 µL of sample protein was loaded into each of the appropriate lanes.
Proteins separated by SDS-PAGE were then transferred to nitrocellu-
lose membranes overnight at 30 V in a cooled (4°C) reservoir
containing transfer buffer (25 mmol/L Tris, 192 mmol/L glycine, and
20% methanol, pH 8.3).18 Nitrocellulose membranes were then re-
moved from the blot apparatus and placed in a Ponceau S staining
solution (0.5% Ponceau S and 1% glacial acetic acid in H2O) for 5
minutes to verify the equal loading of protein in control and treated
samples.19
After equal loading of protein was veriﬁed, the membranes were then
rinsed for an additional 10 minutes and immunoscreened. In brief, the
membranes were blocked in Blotto (5% dried milk dissolved in
50 mmol/L PBS) for at least 1 hour at room temperature. The
membranes were then washed 3 times in PBS plus 0.5% Tween 20.
Next, the membranes were incubated for 1 hour with polyclonal rabbit
anti–IL-1b antibodies (Endogen Inc, Boston, MA) or with normal
rabbit IgG (used as a control) diluted 1:200 in PBS containing 0.5%
Tween 20. After incubation, the membranes were subjected to three
15-minute rinses in PBS containing 0.5% Tween 20. Bound antibody
was detected with the ECL Western Blotting Detection System (Amer-
sham Corp, Arlington Heights, IL). The membranes were incubated
with antirabbit horseradish peroxidase-labeled antibody at a concentra-
tion of 1:2,000 in PBS plus 0.5% Tween 20 at room temperature for 1
hour. After this incubation, the membranes were washed in PBS
containing 0.5% Tween 20, and bound antibody was detected according
to the ECL protocol. The chemiluminescence of the membranes was
detected by exposure to X-OMAT AR5 x-ray ﬁlm (Kodak, Rochester,
NY) in stainless steel cassettes (Sigma Chemical Co, St Louis, MO).
Electrophoretic mobility shift assay (EMSA) of NF-kB activation.
OCIM2 cells (2 3 104 cells/mL) were incubated in the presence of
increasing concentrations of IL-1b at 37°C. Nuclear extracts were then
prepared according to the method of Shreiber et al.20 Brieﬂy, 2 3 106
cells were washed with cold PBS and suspended in a tube with 0.4 mL
of lysis buffer (10 mmol/L HEPES, pH 7.9, 10 mmol/L KCl, 0.1
mmol/LEGTA,1mmol/Ldithiothreitol[DTT],0.5mmol/Lphenylmeth-
ylsulfonyl ﬂuoride [PMSF], 2.0 µg/mL leupeptin, 2.0 µg/mL aprotinin,
and 0.5 mg/mL benzamidine). The tube was then placed on ice, where
the cells were allowed to swell for 15 minutes. Afterward, 12.5 µL of
10% Nonidet P-40 was added. The tube was then vigorously vortexed
for 10 seconds to homogenize its contents and then centrifuged for 30
seconds in a microcentrifuge. The nuclear pellet was resuspended in 25
µLof ice-cold nuclear extraction buffer (20 mmol/LHEPES, pH 7.9, 0.4
mol/L NaCl, 1 mmol/L EDTA, 1 mmol/L EGTA, 1 mmol/L DTT,
1 mmol/L PMSF, 2.0 µg/mL leupeptin, 2.0 µg/mL aprotinin, and 0.5
mg/mLbenzamidine), and the tube was incubated on ice for 30 minutes
with intermittent mixing. This nuclear extract (NE) was then centri-
fuged for 5 minutes in a microcentrifuge at 4°C, and the supernatant was
either used immediately or stored at 270°C for later use. The protein
content was measured by the method of Bradford.21
To determine NF-kB activation, EMSAs were performed as previ-
ously described.22 Brieﬂy, 4 to 5 µg of NE was incubated with 16 fmol
of 32P-end-labeled 45-mer double-stranded NF-kB oligonucleotides
from the human immunodeﬁciency virus-1 long terminal repeat (HIV-
LTR; 58-TTGTTACAAGGGACTT-TCCGCTGGGGGACTTTTCCA-
GGGAGGCGTGG-38) in the presence of 1 to 2 µg of poly(dI-dC) in a
binding buffer (25 mmol/L HEPES, pH 7.9, 0.5 mmol/L EDTA, 0.5
mmol/LDTT, 1% Nonidet P-40, 5% glycerol, and 50 mmol/LNaCl) for
20 minutes at 37°C (we used HIV-LTR–containing NF-kB binding sites
in this assay because myeloid cells are targets for HIV). The DNA-
protein complexes formed were separated from free oligonucleotides on
a 4.5% or 7.5% native polyacrylamide gel using a buffer containing 50
mmol/L Tris, 200 mmol/L glycine, pH 8.5, and 1 mmol/L EDTA, after
which the gel was dried. A mutated oligonucleotide probe was used to
examine the speciﬁcity of NF-kB’s binding to the DNA. For supershift
assays, NE was incubated with the antibodies for 15 minutes at room
temperature before analyzing the NF-kB by EMSA. Radioactive bands
were visualized with a Phosphor Imager (Molecular Dynamics, Sun-
nyvale, CA) using Imagequant software.
TdT-mediated dUTP nick-end labeling (TUNEL) assay for detection
of apoptosis. The apoptosis detection system Fluorescein (Promega,
Madison, WI) was used to perform TUNEL assays.23 Brieﬂy, 4%
Table 1. Clinical Data on AML Patients
Patient
No.
Age
(yr)/
Sex
Cytogenetic
Abnormality
FAB
Category
Hb
(g/dL)
WBC
(3109/L)
Platelets
(3109/L)
%
Blasts
%
Blasts
in BM
1 44/F Misc M2 6.3 129 87 96 51
2 78/M 25,27 M2 10.3 14.5 26 74 77
3 67/F Misc M4 9.9 18.7 95 69 71
4 40/M Dip,2Y M2 8.0 2.9 34 61 73
5 69/F t(15;17) M2 8.2 6.7 53 88 65
6 64/F Misc M1 11.0 146.9 16 92 53
7 45/F 25,27 M1 8.1 6.3 11 53 93
Abbreviations:FAB,French-American-British;Hb,hemoglobin;WBC,
white blood cells; Misc, miscellaneous; Dip, Diploid.
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Triton-100 in PBS.After washing, slides were treated with equilibration
buffer (supplied with kit) and then incubated with a TdT buffer
(prepared according to the manufacturer’s instructions) for 60 minutes.
The staining reaction was terminated by treating the slides with 23 SSC
for 15 minutes. After washing, the slides were treated with an anti-fade
solution and then mounted on slides with glass coverslips and rubber
cement. The slides were analyzed using a ﬂuorescence microscope.
Western immunoblotting for detection of caspase 3 and PARP
proteins. Cell lysates (from 5 3 105 cells) were used as described
above. The following antibodies were used to detect the relevant
proteins:monoclonalmouseantihumanCPP32(TransductionLaborato-
ries, Lexington, KY) to detect uncleaved caspase 3, polyclonal rabbit
antihuman CPP32 (PharMingen, San Diego, CA) to detect cleaved
caspase 3, and mouse antihuman PARP (Upstate Biotechnology, Lake
Placid, NY) to detect PARP. Normal mouse IgG and normal rabbit
serum were used as a control. To conﬁrm detection of uncleaved
caspase 3, Jurkat cells (ATCC) were used; to conﬁrm detection of
cleaved caspase 3 and PARP, 3T3 cells (ATCC) and HeLa cell (ATCC)
nuclear extracts were used, respectively. Bound antibody was detected
according to the ECL protocol (Amersham Life Science) as described
above.
Adherent-cell fractionation. Low-density BM mononuclear cells
obtained by Ficoll-Hypaque (Pharmacia, Piscataway, NJ) fractionation
were incubated in plastic tissue-culture dishes or ﬂasks (Falcon Plastics;
Becton Dickinson, Oxnard, CA) with 10% FCS in a-medium (GIBCO).
The fractionation procedure was repeated until no cells adhered to the
tissue-culture dishes. Nonadherent cells harvested in this way contained
less than 3% monocytes, as conﬁrmed by the following techniques: (1)
microscopic differential counting of at least 100 cells prepared with
Wright’s stain and (2) nonspeciﬁc (a-naphthyl butyrate) esterase
staining and immunocytochemical analysis with CD14 monoclonal
antibodies (Becton Dickinson) to identify monocyte-promonocyte cells,
as previously described.24,25
T-cell depletion. T cells were depleted from the nonadherent
fraction by negative immunomagnetic selection.26 In a modiﬁcation of
this technique, nonadherent BM cells were incubated with CD3
monoclonal antibodies (Becton Dickinson) at a concentration of
1 µg/106 cells in PBS with 0.25% FCS for 30 minutes at 4°C. The
labeled cells were washed 3 times and then incubated with goat
antimouse IgG-conjugated immunomagnetic beads (Advanced Magnet-
ics, Cambridge, MA) at 4°C for 60 minutes in an end-over-end rotation
at a 20:1 bead:cell ratio. Immunomagnetic bead-rosetted cells were
removed with a magnetic particle concentrator (Advanced Magnetics),
and unrosetted cells remaining in suspension were harvested by a
Pasteur pipette. In some experiments, this procedure was repeated
twice. The T-lymphocyte–depleted population contained less than 3%
CD3 cells as assessed by an immunocytochemical technique performed
on cytospun cells.24,25
AML blast colony assay. A previously described method was used
to assayAML blast colony formation.27,28 Brieﬂy, 1 3 105 nonadherent
T-cell–depleted BM cells were plated in 0.8% methylcellulose in
a-medium supplemented with 10% FCS and 50 ng/mL recombinant
human granulocyte-macrophage colony-stimulating factor (rhGM-
CSF; Immunex Corp, Seattle, WA). PAO was dissolved in DMSO and
added at the initiation of the cultures at concentrations ranging from
0.01 to 0.1 µmol/Lin the absence or presence of 10 U/mLof IL-1b. The
cultures were incubated in 35-mm Petri dishes in duplicate or triplicate
for 7 days at 37°C in a humidiﬁed atmosphere of 5% CO2 in air. AML
blast colonies were microscopically evaluated on day 7 of culture. A
blast colony was deﬁned as a cluster of 20 or more cells. Individual
colonies were plucked, smeared on glass slides, and stained to conﬁrm
their leukemic cell composition. (That the AML blast colony assay
identiﬁes blasts rather than normal progenitors had been previously
demonstrated by cytogenetic analysis of colonies obtained using this
assay.29)
RESULTS
PAO inhibits leukemia cell line colony proliferation. We
began studying the effect of PAO on the proliferation of
OCI/AML3 and the OCIM2 cell lines and found that PAO
suppressed their colony-forming cell growth in a dose-
dependent fashion at concentrations ranging from 0.01 to 0.1
µmol/L (Fig 1, upper panel). Although the OCI/AML3 cells
were more sensitive to PAO than were OCIM2 cells, both cell
Fig 1. Effect of PAO on AML cell line colony proliferation. The
upper panel shows the effect of PAO on OCIM2 and OCI/AML3 cells,
and the lower panel shows the effect on HL60 and K562 cells. Each
data point represents the mean colony number 6 SD in triplicate
cultures.
2846 ESTROV ET AL
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K562 cells. Indeed, the growth of OCI/AML3 and OCIM2 cells
was almost completely abolished by PAO at concentrations of
0.05 and 0.1 µmol/L, respectively, whereas HL60 and K562
cells were only partially inhibited (27% and 61%, respectively)
by 0.1 µmol/L(Fig 1, lower panel). The DMSO that was used to
dissolve PAO had no effect on the proliferation of either cell
line.
IL-1b partially reverses the inhibitory effect of PAO. Be-
cause OCI/AML3 and OCIM2 cells, unlike HL60 and K562
cells, proliferate in response to IL-1b,12,30 we also tested
whether IL-1b could affect the inhibitory effect of PAO. We
found that 10 ng/mL IL-1b added at the initiation of culture
partially reversed PAO’s suppressive effect (Fig 2). This is in
keeping with previous studies in which we found that (1)
OCI/AML3 and OCIM2 cells produce large quantities of IL-1b,
which maximally stimulates their proliferation in an autocrine
fashion; (2) the addition of exogenous IL-1b could not signiﬁ-
cantly stimulate their further growth; and (3) IL-1b antibodies
could suppress their growth.12,30 Our current results therefore
suggested that PAO might suppress IL-1b production by
OCI/AML3 and OCIM2 cells.
PAO inhibits IL-1b protein production. In light of the
results given above and published data indicating that PAO
inhibits NF-kB,6 a binding site known to be present in the IL-1b
promoter,31,32 we hypothesized that PAO inhibits IL-1b. To test
this idea, we ﬁrst incubated the cells with PAO and measured
IL-1b protein levels in lysates of OCI/AML3 and OCIM2 cells.
Using ELISAs, we found that 24 hours of incubation with 0.1
µmol/L PAO signiﬁcantly reduced the production of IL-1b but
not of IL-1RA protein by both cell types (Fig 3). These results
indicated that the effect of PAO on IL-1b production is speciﬁc
and does not result from a general suppression of protein
synthesis. Because the ELISA detects both the uncleaved and
cleaved forms of IL-1b, we also used Western immunoblotting
to measure active (cleaved) IL-1b in OCIM2 line, whose
morphology and origin do not resemble those of APL, and
Fig 2. Effect of PAO and IL-1b on OCIM2 and OCI/AML3 colony
proliferation. Each data point represents the mean colony number 6
SD in triplicate cultures. PAO was added to each culture at a final
concentration of 0.08 mmol/L and IL-1b at 10 ng/mL.
Fig 3. Effect of PAO on the production of IL-1b and IL-1RA by
OCIM2 and OCI/AML3 cells. Cells were incubated in the presence or
absence of 1.0 mmol/L PAO for 24 hours. The amount of IL-1b (upper
panel) and IL-1RA (lower panel) produced by these cells was then
assessed by ELISA as described in Materials and Methods.
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mature IL-1b (Fig 4).
PAO inhibits IL-1b–induced NF-kB activation. Because
IL-1 is known to activate NF-kB,8 we sought to determine
whether IL-1b activates NF-kB in OCIM2 cells. We did so by
incubating the cells for 1 hour in the presence of increasing
concentrations of IL-1b and then testing them for NF-kB
activity by EMSA. As shown in Fig 5A, NF-kB activation
increased with IL-1b dose, reaching a maximum at 10 ng/mL
IL-1b. Next, we examined the effect of increasing concentra-
tions of PAO on IL-1b–induced NF-kB activation. For this,
OCIM2 cells were treated for 1 hour with 0.1, 0.3, and 1.0
µmol/L PAO and then for 1 more hour with the addition of 10
ng/mL of IL-1b to activate NF-kB. As shown in Fig 5B, PAO
abolished the IL-1b–induced NF-kB activation in a dose-
dependent manner, with maximum inhibition occurring at a
PAO concentration of 1.0 µmol/L (the minor activation of
NF-kB induced by 1.0 µmol/L of PAO was not signiﬁcant by a
quantitative analysis, as found in our previous study33).
The speciﬁcity of the NF-kB band in the EMSAs was
demonstrated by its ability to compete with a cold oligo but not
with an oligo containing a mutated NF-kB site. Thus, these
results show that PAO blocked IL-1b–induced NF-kB activa-
tion.
PAO induces apoptosis in OCIM2 cells. Because a lack of
NF-kB activation may abolish cellular proliferation and lead to
apoptotic cell death34,35 and the arsenic compound AS2O3 can
induce apoptosis in APL cells,4 we hypothesized that PAO
might have a similar effect on OCIM2 cells. To test this idea,
OCIM2 cells at the peak of their growth were washed and then
incubated in PBS in the presence and absence of 0.1 µmol/L
PAO for 4, 6, and 8 hours. Using the TUNEL assay, we found
that PAO induced apoptosis in these AML cells and that longer
exposure to this compound increased the number of cells
undergoing apoptotic cell death (Fig 6).
PAO induces apoptosis by cleaving caspase 3. To deter-
mine the mechanism by which PAO induces apoptosis, OCIM2
cells were incubated in the absence and presence of 0.06, 0.08,
0.1, 0.4, 0.6, and 0.8 µmol/L of PAO for 4 hours and then
harvested for Western immunoblot analysis as described above.
As shown in Fig 7, PAO downregulated the expression of
uncleaved PARP protein in a dose-dependent fashion. Because
caspase activation seems to be an essential step in PARP
cleavage and cellular apoptosis36-38 and because caspase 339-41
appears to be involved in apoptosis induced in leukemia
cells,42-44 we measured the levels of uncleaved and cleaved
caspase 3 in OCIM2 AML cells. As shown in Fig 8, we found
that the incubation of OCIM2 cells with 0.08 and 0.1 µmol/L of
PAO upregulated the levels of the biologically active (cleaved)
caspase 3 and the inactivated (cleaved) form of the DNA-repair
enzyme PARP,36-38 thereby activating the apoptotic cascade. To
further investigate whether caspase activation is essential for
PAO-induced apoptosis, we incubated OCIM2 cells with 0.1
µmol/L of PAO with and without 50 µmol/L of the caspase
inhibitor Z-DEVD-FMK.45,46 Using the TUNEL assay, we
Fig 4. Effect of PAO on the production of mature IL-1b by OCIM2
cells. Cells were incubated in the presence and absence of 0.1 mmol/L
PAO. The amount of mature IL-1b protein produced by these cells was
then assessed by Western immunoblotting. The arrow points to the
17.5-kD mature IL-1b protein. Lane C shows control mature IL-1b
protein, lane 1 shows protein from cells incubated in tissue culture
media with DMSO, and lane 2 shows protein from cells incubated
with PAO.
Fig 5. (A) Activation of NF-kB
by IL-1b. OCIM2 cells (2 3 106/
mL) were incubated at 37°C with
increasing concentrations of
IL-1b for 1 hour. Nuclear extracts
were then prepared and assayed
for NF-kB as described above.
(B) Inhibition of IL-1b–induced
NF-kB activation by PAO. Cells
were treated with PAO for 1 hour
and then with IL-1b for 1 hour.
Nuclear extracts were prepared
and assayed for NF-kB activity
as described in Materials and
Methods.
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apoptosis (Fig 9).
PAO inhibits fresh AML blast colony-forming cell prolifera-
tion. We then studied the effect of PAO on the proliferation of
fresh AML marrow blast colony-forming cells. For this, we
used diagnostic BM cells from 7 AML patients whose clinical
characteristics are depicted inTable 1.As shown in Fig 10, PAO
inhibited AML blast colony-forming cell growth in a dose-
dependent manner in all of the samples studied. Similar to its
effect on AML cell lines, IL-1b, when added at the initiation of
culture, partially reversed the inhibitory effect of PAO (Fig 11).
DISCUSSION
Throughout history, arsenic compounds have been useful
therapeutic agents against many human ailments.47 The antileu-
kemic properties of arsenic have been known since the mid
1800s.47Arsenicals together with irradiation were the treatment
of choice for chronic myelogenous leukemia until busulfan was
Fig 6. Induction of apoptosis
by PAO. OCIM2 cells were incu-
batedintheabsence(A)andpres-
ence of PAO for 4 (B), 6 (C), and 8
(D) hours. Apoptotic cells appear
yellow.
Fig 9. Effect of Z-DEVD-FMK
on PAO-induced apoptosis.
OCIM2 cells were incubated for 6
hours without any drug (A), with
0.1 mmol/L of PAO (B), with 50
mmol/L of Z-DEVD-FMK (C), and
with both PAO and Z-DEVD-FMK
(D). Apoptotic cells appear yel-
low.
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research has concentrated on the toxic effects of arsenic
compounds. Several investigators have shown a relationship
between ingestion of or exposure to various arsenicals and the
occurrence of lung,49 skin,50 bladder,51 and hepatocellular52
cancer, and numerous studies have demonstrated that arsenic
compounds are environmental carcinogens.53Yet, recent reports
from China show that As2O3 and arsenic disulﬁde can induce
complete remission of APL2,3,54,55 via pathways different from
those used by retinoids.4,56 These studies have prompted other
investigators to explore the effects of various arsenicals onAPL
and other leukemias.57-59
The arsenical PAO is a membrane-permeable PTPase inhibi-
tor that is active in hematopoietic cells.5,60 At high concentra-
tions it causes nonspeciﬁc leakage in mitochondria. PAO also
has been shown to inhibit early elevations in cytosolic calcium
concentrations61 and to interfere with the insulin transduction
pathway.62 Because PAO is also known to inhibit the activation
of NF-kB6 in hematopoietic cells, we therefore sought to
investigate its effects onAML.
NF-kB is a ubiquitous transcription factor and a major
regulator of the immune system through its induction of
expression of various inﬂammatory cytokines including IL-
1b.32,33 NF-kB exists in the cytoplasm as a heterotrimeric
complex with the inhibitor IkBa (reviewed in Seibenlist et al63).
Within minutes of activation by inﬂammatory agents such as
IL-1b,I kBa undergoes phosphorylation, ubiquitination, and
proteolytic degradation, thus releasing the NF-kB p50-p65
complex for translocation from the cytoplasm to the nucleus.
Whereas the activation of NF-kB induces cellular proliferation8
and protects cells from apoptotic cell death,35,64 its inhibition
enhances spontaneous apoptosis34 or apoptosis induced by
various stimuli such as irradiation or cytotoxic drugs.35
Several growth factors regulate hematopoietic cell survival
by interfering with apoptotic signals.65-67 One of these is the
cytokine IL-1b, a proinﬂammatory protein that has been
implicated in early events in hematopoiesis. It induces the
production of various cytokines and synergizes with several
growthfactorsinstimulatinghematopoieticprogenitormultipli-
cation.31,68 In addition, as we and others have found, IL-1b
plays an important role in AML cell proliferation (reviewed in
Estrov et al68). Suppression of IL-1 production or inhibition of
its interaction with the corresponding cellular receptors signiﬁ-
cantly inhibits AML progenitor cell growth.9-12,30,69 Further-
more, the activation of NF-kB appears to be an important step in
the molecular events leading to IL-1b production8,31,32 and, as a
result, also appears to stimulate leukemia cell proliferation.
In this light, we assumed that an effective NF-kB inhibitor
such as PAO might either suppress the production of IL-1b,
inhibit the direct NF-kB–mediated leukemia cell proliferation,7
or both. In a previous study70 we have already demonstrated that
PAO can block the NF-kB–dependent expression of various
Fig 7. Effect of PAO on PARP protein expression. OCIM2 cells were
incubated in the absence and the presence of increasing concentra-
tions of PAO. The results shown here were obtained after incubating
OCIM2 cells for 4 hours.
Fig 8. Effect of PAO on caspase 3 and PARP cleavage. OCIM2 cells
were incubated without PAO (lane C) and with it at a concentration of
0.08 mmol/L (lane 2) or 0.1 mmol/L (lane 1) for 8 hours. Cleavage of
caspase 3 was already detected after 4 hours. Increments in the levels
of cleaved caspase 3 (A) and cleaved PARP (B) are depicted.
Fig 10. Effect of PAO on fresh AML blast colony-forming cells.
After adherent cell fractionation of adherent cells and depletion of T
lymphocytes, remaining cells were cultured in a clonogenic assay
with PAO at concentrations ranging from 0.01 to 0.1 mmol/L. AML
colonies are presented as the percentage of control (the mean
number of colonies obtained in the absence of PAO). Data from
patients no. 1 through 6 are depicted.
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activity of NF-kB. Now, in our current study, we have found
that PAO inhibits the proliferation of HL60 and K562 and, more
signiﬁcantly, of the IL-1–responsive OCI/AML3 and OCIM2
cells, that PAO suppressed the growth of the IL-1–responsive
lines in a dose-dependent manner, and that IL-1b partially
reverses this inhibitory effect. Together, these results suggest
that at least part of the PAO-induced suppression observed in
the present study was mediated through PAO’s inhibition of
IL-1b production. Indeed, incubation of the OCI/AML3 and
OCIM2 cell lines in the presence of PAO almost completely
abolished the production of IL-1b but not IL-1RA protein. In
addition, PAO signiﬁcantly inhibited the IL-1b–induced NF-kB
activity. Whereas IL-1b activated NF-kB in these cells, PAO
suppressed it in a dose-dependent fashion. Thus, PAO inhibited
both IL-1b production and the IL-1b–mediated activation of
NF-kB, resulting in an additional reduction in the production of
IL-1b.
Because NF-kB activation suppresses the signals for cell
death and inhibition of NF-kB may result in apoptotic cell
death,34,35 we tested the effect of PAO on the induction of
apoptosis. We found that treatment of leukemia cells with PAO
induced apoptotic cell death. Our results agree with those of
Jimi et al,71 who recently found that inhibition of NF-kBb y
oligodeoxynucleotides to p65 and p50 abolished the IL-1–
induced survival of osteoclasts.
Because most cell types require activation of a speciﬁc
proteolytic cascade if apoptosis is to occur, we also wondered
whether PAO might help activate that cascade in AML cells. In
particular, we chose to study the effect of PAO on caspase 3.
Caspase 3 is a key executioner of apoptosis39-41 whose activa-
tion downstream in the apoptotic cascade is essential for
leukemia cell apoptosis.33,42,43 Moreover, the activation of
caspase 3 results in the cleavage of cellular substrates critical
for cell survival, such as PARP and lamins, which, in turn,
precipitates the morphological changes characteristic of apopto-
sis (reviewed in Cohen72). This approach of ours found support
in the work of Zhang et al,73 who had already shown that arsenic
trioxide downregulates the expression of bcl-2, an antiapoptotic
protein known to inhibit the activation of caspase 3. As hoped,
we found that PAO activated caspase 3 and consequently
cleaved PARP. Interestingly, Barkett et al74 have recently
reported that caspase 3 cleaves human Ik-B-a in vitro at a
conservedAsp-Ser sequence, thus creating a dominant inhibitor
that prevents the activation of NF-kB and thereby adding
another death signal.
Similar to its effect on AML cell lines and comparable to the
effect of other IL-1 inhibitors,10-12,30 PAO suppressed AML
progenitor proliferation and had its inhibitory effect partially
reversed by IL-1b. These results indicate that the inhibition of
IL-1b production is part of PAO’s inhibitory mechanism in
AMLcells.
Taken together, our data suggest that PAO, either through
inhibition of NF-kB, suppression of IL-1b production, or both,
may eliminate leukemia cells and so prove to be an effective
agent in the treatment ofAML.
ACKNOWLEDGMENT
The authors thank Jude Richard for editing the manuscript.
REFERENCES
1. Estey E: Treatment of refractoryAML. Leukemia 10:932, 1996
2. Huang SL, Guo AX, Xiang Y, Wang XB, Ling HJ, Fu L: Clinical
study on the treatment of APL mainly with composite indigo naturalis
tablets. Chin J Hematol 16:26, 1995
3. Chen GQ, Shi XG, Tang W, Xiong SM, Zhu J, Cai X, Han ZG, Ni
JH, Shi GY, Jia PM, Liu MM, He KL, Niu C, Ma J, Zhang P, Zhang TD,
Paul P, Naoe T, Kitamura K, Miller W, Waxman S, Wang ZY, de The H,
Chen SJ, Chen Z: Use of arsenic trioxide (As2O3) in the treatment of
acute promyelocytic leukemia (APL): I As2O3 exerts dose-dependent
dual effects onAPLcells. Blood 89:3345, 1997
4. Chen G-Q, Zhu J, Shi X-G, Ni J-H, Zhong H-J, Si G-Y, Jin X-L,
Tang W, Li X-S, Xong S-M: In vitro studies on cellular and molecular
mechanisms of arsenic trioxide (As2O3) in the treatment of acute
promyelocytic leukemia: Expression and modulation of PML-RARa/
PMLproteins. Blood 88:1052, 1996
5. Oetken C, von Willebrand M, Autero M, Tutu T, Andersson L,
Mustelin T: Phenylarsine oxide augments tyrosine phosphorylation in
hematopoietic cells. Eur J Haematol 49:208, 1992
6. Singh S, Aggarwal BB: Protein-tyrosine phosphatase inhibitors
blocktumornecrosisfactor-dependentactivationofthenucleartranscrip-
tion factor NF-kB. J Biol Chem 270:10631, 1995
7. Tenen DG, Hromas R, Licht JD, Zhang D-E: Transcription factors
normal myeloid development and leukemia. Blood 90:489, 1997
8. Seibenlist U, Franzoso G, Brown K: Structure regulation and
function of NF-kappa B.Annu Rev Cell Biol 10:405, 1994
9. Estrov Z, Kurzrock R, Estey E, Wetzler M, Ferrajoli A, Harris D,
Blake M, Gutterman JU, Talpaz M: Inhibition of acute myelogenous
leukemia blast proliferation by IL-1 receptor antagonist and soluble
IL-1 receptors. Blood 79:1938, 1992
Fig 11. Effect of PAO and IL-1b on proliferation of AML colony-
forming cells. Data from triplicate cultures of marrow samples from
patient no. 6 (Expt I) and patient no. 7 (Expt II) are depicted. PAO (0.1
mmol/L) and IL-1b (10 ng) were added at the initiation of culture.
EFFECT OF PAO ON AML CELLS 2851
For personal use only. on November 3, 2014.  by guest    www.bloodjournal.org From 10. RambaldiA,Torcia M, Bettoni S,Vannier E, BarbuiT, ShawAR,
Dinarello CA, Cozzolino F: Modulation of cell proliferation and
cytokine production in acute myeloblastic leukemia by interleukin-1
receptor antagonist and lack of its expression by leukemic cells. Blood
78:3248, 1991
11. Yin M, Gopal V, Banavali S, Gartside P, Preisler H: Effects of an
IL-1 receptor antagonist on acute myeloid leukemic cells. Leukemia
6:898, 1992
12. Estrov Z, Black RA, Sleath PR, Harris D, Van Q, LaPushin R,
Estey E, Talpaz M: Effect of interleukin-1b converting enzyme
inhibitor on acute myelogenous leukemia progenitor proliferation.
Blood 86:4594, 1995
13. Wang C, Curtis JE, Minden MD, McCulloch EA: Expression of
retinoic acid receptor gene in myeloid leukemia cells. Leukemia 3:264,
1989
14. Papayannopoulou T, Nakamoto B, Kurachi S, Tweeddale M,
Messner H: Surface antigen proﬁle and globin phenotype of two new
humanerythroleukemialines:Characterizationandinterpretation.Blood
72:1029, 1988
15. Estrov Z, Cohen A, Gelfand EW, Freedman MH: Synergistic
antiproliferative effects on HL-60 cells: Deferoxamine enhances cyto-
sine arabinoside methotrexate and daunorubicin cytotoxicity. Am J
Pediatr Hematol Oncol 10:288, 1988
16. Estrov Z, Kurzrock R, Wetzler M, Kantarjian H, Blake M, Harris
D, Gutterman JU, Talpaz M: Suppression of chronic myelogenous
leukemia colony growth by interleukin-1 (IL-1) receptor antagonist and
soluble IL-1 receptors: A novel application for inhibitors of IL-1
activity. Blood 78:1476, 1991
17. Laemmli UK: Cleavage of structural proteins during the assem-
bly of the head of bacteriophage T4. Nature (London) 227:680, 1970
18. Towbin H, Staehelin T, Gordon J: Electrophoretic transfer of
proteins from polyacrylamide gels to nitrocellulose sheets: Procedure
and some applications. Proc NatlAcad Sci USA76:4350, 1979
19. Gershoni JM, Palade GE: Protein blotting: Principles and
applications.Anal Biochem 131:1, 1983
20. Schreiber E, Matthias P, Muller MM, Schaffner W: Rapid
detection of octamer binding proteins with ‘‘mini-extracts’’ prepared
from a small number of cells. NucleicAcids Res 17:6419, 1989
21. Bradford MM: A rapid and sensitive method for the quantitation
of microgram quantities of protein utilizing the principle of protein-dye
binding.Anal Biochem 72:248, 1976
22. Chaturvedi M, Kumar A, Darnay B, Chainy GBN, Aggarwal S,
Aggarwal BB: Sanguinarine (pseudochelerythrine) is a potent inhibitor
of NF-kappa B activation, I-kappa B alpha phosphorylation, and
degradation. J Biol Chem 272:30129, 1997
23. Gavrieli Y, Sherman Y, Ben-Sasson SA: Identiﬁcation of pro-
grammed cell death in situ via speciﬁc labeling of nuclear DNA
fragmentation. J Cell Biol 119:493, 1992
24. Shaw G, Levy PC, LoBuglio AF: Human monocyte antibody-
dependent cell-mediated cytotoxicity to tumor cells. Clin Invest 62:
1172, 1978
25. Estrov Z, Grunberger T, Chan HSL, Freedman MH: Juvenile
chronic myelogenous leukemia: Characterization of the disease using
cell cultures. Blood 67:1382, 1986
26. Bertoncello I, Bradley R, Watt SM: An improved negative
immunomagnetic selection strategy for the puriﬁcation of primitive
hemopoietic cells from normal bone marrow. Exp Hematol 19:95, 1991
27. Buick RN, Till JE, McCulloch EA:Acolony assay for prolifera-
tive blast cells circulating in myeloblastic leukemia. Lancet 1:862, 1977
28. Minden MD, Buick RN, McCulloch EA: Separation of blast cells
and T lymphocyte progenitors in the blood of patients with acute
myeloblastic leukemia. Blood 54:186, 1979
29. Freedman MH, Chan HSL, Chang L: Childhood erythroleuke-
mia: Studies on pathogenesis using colony assays. Am J Pediatr
Hematol Oncol 8:2, 1986
30. Peleg S, Qui H, Reddy S, Harris D, Van Q, Estey EH, Talpaz M,
Estrov Z: 125-dihyroxyvitamin D3 and its analogs inhibit proliferation
ofacutemyelogenousleukemiaproliferationbysuppressinginterleukin-
1b-mediated signals. J Clin Invest 100:1716, 1997
31. Dinarello CA: Biologic basis for interleukin-1 in disease. Blood
87:2095, 1996
32. Oneill LAJ: Interleukin-1 signal transduction. Int J Clin Lab Res
25:169, 1995
33. Singh S, Aggarwal BB: Protein-tyrosine phosphatase inhibitors
blocktumornecrosisfactor-dependentactivationofthenucleartranscrip-
tion factor NF-kB. J Biol Chem 270:10631, 1995
34. Ozaki K, Takeda H, Iwahashi H, Kitano S, Hanezawa S: NF-kB
inhibitors stimulate apoptosis of rabbit mature osteoclasts and inhibit
bone resorption by these cells. FEBS Lett 410:297, 1997
35. Wang CY, Mayo MW, Baldwin AS: TNF- and cancer therapy-
induced apoptosis: Potentiation by inhibition of NF-kB. Science
274:784, 1996
36. Ashkenas J, Werb Z: Proteolysis and the biochemistry of
life-or-death decisions. J Exp Med 183:1947, 1996
37. Martin S, Green D: Protease activation during apoptosis: Death
by a thousand cuts? Cell 82:349, 1995
38. Kumar S, Harvey NL: Role of multiple cellular proteases in the
execution of programmed cell death. FEBS Lett 375:169, 1995
39. Nicholson DW,AliA,Thornberry NA,Vaillancourt JP, Ding CK,
Gallant M, Gareau Y, Griffin PR, Labelle M, Lazebnik Y: Identiﬁcation
and inhibition of the ICE/CED-3 protease necessary for mammalian
apoptosis. Nature 376:37, 1995
40. Tewari M, Quan LT, O’Rourke K: Yama/CPP32 beta a mamma-
lian homolog of CED-3 is a Crm-A-inhibitable protease that cleaves the
death substrate poly (ADP-ribose) polymerase. Cell 81:801, 1995
41. Fernandes-Alnemri T, Litwack G, Alnemri ES: CPP32 a novel
human apoptotic protein with homology to Caenorhabditis elegans cell
death protein Ced-3 and mammalian interleukin-1b-converting en-
zyme. J Biol Chem 269:30761, 1994
42. Datta R, Banach D, Kojima H, Talanian RV, Alnemri ES, Wong
WW, Kufe DW:Activation of the CPP32 protease in apoptosis induced
by 1-b-D arabinofuranosylcytosine and other DNA-damaging agents.
Blood 88:1936, 1996
43. Ibrado AM, Huang Y, Fang G, Liu L, Bhalla K: Overexpression
of Bcl-2 or Bcl-xL inhibits ara-C induced CPP32/Yama protease activity
and apoptosis of human acute myelogenous leukemia HL-60 cells.
Cancer Res 56:4743, 1996
44. SukukiA, MatsuzawaA, Kato M: Involvement of CPP32/Yama-
like protease in CPT-11-induced death signal transduction pathway.
Toxicol In Vitro 10:693, 1997
45. Nicholson DW: ICE/CED3-like proteases as therapeutic targets
for the control of inappropriate apoptosis. Nat Biotechnol 14:297, 1996
46. Schlegel J, Peters I, Orrenius S, Miller DK, Thorenberg NA,
Yamin TT, Nicholson DW: CPP32/apopain is a key interleukin-1 beta
converting enzyme-like protease involved in FAS-mediated apoptosis. J
Biol Chem 271:1841, 1996
47. Jolliffe D:Ahistory of the use of arsenicals in man. J R Soc Med
86:287, 1993
48. Sears D: History of the treatment of chronic myelocytic leuke-
mia.Am J Med Sci 296:85, 1998
49. Qiao YL, Taylor PR, Yao SX, Erozan YS, Luo XC, Barrett MJ,
Yan QY, Giffen CA, Huang SQ, Maher MM, Forman MR, Tockman
MS: Risk factors and early detection of lung cancer in a cohort of
Chinese tin miners.Ann Epidemiol 7:533, 1997
50. Hsueh Y, Chiou H, Huang Y, Wu W, Huang C, Yang M, Lue L,
Chen G, Chen C: Serum beta-carotene level, arsenic methylation
capability, and incidence of skin cancer. Cancer Epidemiol Biomarkers
Prev 6:589, 1997
51. Johansson S, Cohen SM: Epidemiology and etiology of bladder
cancer. Semin Surg Oncol 13:291, 1997
2852 ESTROV ET AL
For personal use only. on November 3, 2014.  by guest    www.bloodjournal.org From 52. Chen C, Yu M, Liaw Y: Epidemiological characteristics and risk
factors of hepatocellular carcinoma. J Gastroenterol Hepatol 12:S294,
1997
53. Valberg P, Beck B, Bowers T, Keating J, Bergstrom P, Boardman
P: Issues in setting health-based cleanup levels for arsenic in soil. Regul
Toxicol Pharmacol 26:219, 1997
54. Sun HD, Ma L, Hu XC, Shang TD: Ai-Lin I treated 32 cases of
acute promyelocytic leukemia. Chin J Integrat Chin West Med 12:170,
1992
55. Shen ZX, Chen GQ, Ni JH, Li XS, Xiong SM, Qui QY, Zhu J,
Tang W, Sun GL, Yang KQ, Chen Y, Zhou L, Fang Z-W, Wang Y-T, Ma
J, Zhang P, Zhang T-D, Chen S-J, Chen Z, Wang Z-Y: Use of arsenic
trioxide (As2O3) in the treatment of acute promyelocytic leukemia
(APL): II. Clinical efficacy and pharmacokinetics in relapsed patients.
Blood 89:3354,1997
56. Kitamura K,Yoshida H, Ohno R, NaoeT:Toxic effects of arsenic
(As31) and other metal ions on acute promyelocytic leukemia cells. Int
J Hematol 65:179, 1997
57. Kitamura K, Kiyoi H,Yoshida H, Tobita T, TakeshitaA, Ohno R,
Naoe T: New retinoids and arsenic compounds for the treatment of
refactory acute promyelocytic leukemia: Clinical and basic studies for
the next generation. Cancer Chemother Pharmacol 40:S36, 1997 (suppl)
58. Koing A, Wrazel L, Warrell RP, Rivi R, Pandolﬁ P, Jakubowski
A, Gabrilove J: Comparative activity of melarsoprol and arsenic
trioxide in chronic B-cell leukemia lines. Blood 90:562, 1997
59. Wang ZG, Rivi R, Delva L, Konig A, Scheinberg DA, Gamba-
corti-Passerini C, Gabrilove JL, Warrel PR, Pandolﬁ PP: Arsenic
trioxide and melarsoprol induce programmed cell death in myeloid
leukemia cell lines and function in a PML and PML-RAR alpha
independent manner. Blood 92:1497, 1998
60. Oetken C, vonWillebrand M, Marie-CardineA, Pessa-Morikawa
T, Stahls A, Fisher S, Mustelin T: Induction of hyperphosphorylation
and activation of the p56lck protein tyrosine kinase by phenylarsine
oxide, a phosphotyrosine phosphatase inhibitor. Mol Immunol 31:1295,
1994
61. Deckert M, Aussel C, Bernard A, Breittmayer J: Phenylarsine
oxide and phorbol myristate acetate inhibit the CD3-induced rise of
cytosolic Ca21 in Jurkat cells by reﬁlling internal Ca21 stores.
Biochem J 297:567, 1994
62. Bergum N: Phenylarsine oxide inhibits insulin-stimulated pro-
tein phosphatase 1 activity and GLUT-4 translocation. Am J Physiol
267:E14, 1994
63. Seibenlist U, Franzoso G, Brown K: Structure regulation and
function of NF-kappa B.Annu Rev Cell Biol 10:405, 1994
64. Gini DK,Aggarwal BB: Constitutive activation of NF-kB causes
resistance to apoptosis in human cutaneous T-cell lymphoma Hut-78
cells. J Biol Chem 273:14008, 1998
65. Lotem J, Peledkamar M, Groner Y, Sachs L: Cellular oxidative
stress and the control of apoptosis by wild-type P53 cytotoxic com-
pounds and cytokines. Proc NatlAcad Sci USA93:9166, 1996
66. Brodsky RA, Bedi A, Jones RJ: Are growth factors leukemo-
genic? Leukemia 10:175, 1996
67. Jacobsen FW, Veiby OP, Stokke T, Jacobsen SEW: TNF-alpha
bidirectionally modulates the viability of primitive murine hematopoi-
etic progenitor cells in vitro. J Immunol 157:1193, 1996
68. Estrov Z, Kurzrock R,Talpaz M: Cytokines and their antagonists
in myeloid disorders. Semin Hematol 32:220, 1995
69. DinarelloCA:Interleukin-1andinterleukin-1antagonism.Blood
77:1627, 1991
70. Dhawan S, Singh S, Aggarwal BB: Induction of endothelial cell
surface adhesion molecules by tumor necrosis factor is blocked by
protein tyrosine phosphatase inhibitors: Role of the nuclear transcrip-
tion factor NF-kB. Eur J Immunol 27:2172, 1997
71. Jimi E, Nakamura I, Ikebe T,Akiyama S, Takahashi N: NF-kBi s
involved in the survival of osteoclasts promoted by interleukin-1. J Biol
Chem 273:8799, 1998
72. Cohen GM: Caspases: The executioners of apoptosis. Biochem J
326:1, 1996
73. Zhang W, Ohnishi K, Shigeno K, Fujisawa S, Naito K, Naka-
mura S, Takeshita K, Takeshita A, Ohno R: The induction of apoptosis
and cell cycle arrest by arsenic trioxide in lymphoid neoplasms.
Leukemia 12:1383, 1998
74. Barkett M, Xue D, Horvitz HR, Gilmore TD: Phosphorylation of
Ik-B-a inhibits its cleavage by caspase CPP32 in vitro. J Biol Chem
47:29419, 1997
EFFECT OF PAO ON AML CELLS 2853
For personal use only. on November 3, 2014.  by guest    www.bloodjournal.org From 